SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

WorldFinancial

WorldFinancial is currently facing intense scrutiny as community members debate whether the project is a calculated wealth transfer scheme or a deeply undervalued asset primed for a supply shock. Sentiment remains sharply divided, with frustrated investors highlighting recent token unlocks and legal controversies involving high-profile figures, while others aggressively advocate for accumulating positions in anticipation of a governance-led turnaround and future utility rollouts.

Green Plains, Inc. engages in the production of fuel-grade ethanol and corn oil, the provision of grain handling, and storage commodity marketing and distribution services. It operates through the Ethanol Production and Agribusiness and Energy Services segments. The Ethanol Production segment produces ethanol, distillers' grain, and corn oil at ethanol plants in Indiana, Iowa, Minnesota, Nebraska, Tennessee, and Texas. The Agribusiness and Energy Services segment includes grain handling and storage, commodity marketing and merchant trading for company-produced and third-party ethanol, distillers grains, renewable corn oil, natural gas, and other commodities. The company was founded in June 2004 and is headquartered in Omaha, NE.

Green Plains Inc

Green Plains is garnering attention as investors track its progress in carbon capture and operational efficiency, alongside ongoing discussions regarding its strategic focus on sustainable ingredients. The community remains closely engaged with the company's potential to benefit from government tax credits and broader biofuel policy shifts.

MATH is a one stop crypto solution platform which contains MathWallet, MATH VPOS Pool, MathDEX, MATH dApp Store, MATH Staking, MATH Pay, MATH Chain, etc.

MATH

MATH is seeing increased community chatter as traders speculate on a potential breakout driven by its low market cap and historical volatility. While some participants remain frustrated by stagnant price action and past pump-and-dump cycles, others are actively accumulating tokens in anticipation of a wider altcoin market recovery.

Stafi is the first DeFi protocol unlocking liquidity of staked assets. Users can stake PoS tokens through Stafi and receive rTokens in return, which are available for trading while still earning staking rewards. FIS is the native token on Stafi Chain. FIS is required to provide security to the network by staking, pay for transaction fees on the Stafi chain, mint &amp; redeem rTokens.

StaFi

StaFi (FIS) is attracting attention as a liquid staking protocol with a low market cap, driven by community discussions around a token burn proposal, a new roadmap, and hopes for a deflationary model. Despite recent exchange delisting concerns, retail participants are actively monitoring the asset for potential upside, focusing on its utility as a staking layer and current technical momentum.

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin is attracting significant attention as community members discuss its potential as an undervalued infrastructure play for on-chain AI agents. Investors are actively debating the token's accumulation phase, with many focusing on long-term holding strategies despite recent price volatility and retail-versus-bot market dynamics.

Stubhub Holdings, Inc. provides online ticket selling services. It also provides services for buyers and sellers of tickets for sports, concerts, theater, and other live entertainment events. The company was founded by Eric H. Baker in 2000 and is headquartered in New York, NY.

Stubhub Holdings Inc. - Ordinary Shares - Class A

StubHub

StubHub is currently the subject of intense community debate as investors weigh strong fundamental metrics, such as EBITDA growth and new partnerships, against concerns regarding regulatory scrutiny and negative sentiment surrounding its recent public debut. Market participants are closely watching the stock for potential reversal patterns as bullish traders look for value in the secondary ticketing marketplace, while skeptics remain focused on ongoing legal risks and downward price momentum.

XYO is the original and one of the largest Decentralized Physical Infrastructure Networks (DePIN), boasting over 10 million nodes and consistently leading DePIN in both scale and revenue generation. Launching its Mainnet ahead of any other DePIN, XYO specializes in collecting and validating real-world data, bridging it seamlessly to Web3 and Web2 companies across AI, geolocation, and other critical data sectors. At the core of XYO are Proof of Location and Proof of Origin technologies, enabling accurate validation of real-world data for innovative use cases such as Real-World Asset (RWA) tracking, DePIN applications, real-world gaming, and treasure hunts. Recently, XYO expanded its ecosystem by launching the XYO Layer One blockchain, purpose-built to support the intensive data demands of DePIN, RWA, AI, and similar data-driven industries. XYO employs a unique dual-token model: XYO Token: An externally traded token supporting the DePIN ecosystem, rewards, staking, and governance, enhancing overall ecosystem value and scarcity.   XL1 Token: Internal to the XYO Layer One blockchain, facilitating transactions, gas fees, and other blockchain-specific use cases. The dual-token economics are strategically designed to increase scarcity and promote sustainable growth. The XYO token is available on major exchanges, including Coinbase. The XL1 token will launch publicly later in 2025. To accelerate network adoption and growth, XYO created the popular COIN app. Beyond the XYO Foundation, the team founded the U.S.-based, for-profit entity XY Labs Inc., notable as the first U.S. crypto company qualified by the SEC for a Regulation A offering, permitting share sales to both accredited and non-accredited investors. XY Labs further stands out as one of the pioneering U.S. companies to tokenize and publicly list its shares. These tokenized shares trade as $XYLB on the tZERO ATS, positioning XY Labs prominently in the growing wave of Real-World Asset (RWA) tokenization.

XYO Network

XYO Network is facing intense community scrutiny as investors debate whether the project is a long-term DePin investment or a recurring pump-and-dump scheme. While some supporters are aggressively accumulating tokens based on potential future use cases, many long-term holders are venting frustration over stagnant price action, a perceived lack of meaningful leadership updates, and confusion surrounding the recent token ecosystem developments.

ARK ETF Trust - ARK Innovation ETF

ARK Innovation ETF

The ARK Innovation ETF is facing intense scrutiny and mixed community sentiment as recent underperformance compared to broader indices fuels debates over its disruptive growth strategy. Investors are actively discussing the fund's heavy exposure to volatile tech names, ongoing portfolio rebalancing, and its struggle to capture the momentum seen in AI infrastructure and semiconductor leaders.

Realty Income Corp. is a real estate company, which engages in generating dependable monthly cash dividends from a consistent and predictable level of cash flow from operations. The company was founded by William E. Clark, Jr. and Evelyn Joan Clark in 1969 and is headquartered in San Diego, CA.

Realty Income Corp.

Realty Income (O) is trending as income-focused investors weigh a consistent monthly dividend against concerns over rising interest expenses and valuation. The community remains divided, with some actively wheeling the stock and reinvesting dividends to build long-term positions, while others express frustration over stagnant price appreciation compared to broader market growth.

Evolution Metals & Technologies Corp. engages in developing a global supply chain for critical minerals and materials. It focuses on automotive, renewable energy, and military and defense sectors. The company is headquartered in West Palm Beach, FL.

Evolution Metals & Technologies Corp.

Evolution Metals & Technologies Corp. Common Stock

Evolution Metals & Technologies Corp. (EMAT) is gaining momentum as investors eye its strategic pivot toward domestic rare earth magnet production and supply chain independence. The community is actively debating the stock's potential as a low-float play while tracking its recent operational expansions and aggressive technological integration.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Gilead Prices $3 Billion of Senior Unsecured Notes

Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, today announced the pricing of senior unsecured...

Is It Worth Investing in Gilead (GILD) Based on Wall Street's Bullish Views?

Based on the average brokerage recommendation (ABR), Gilead (GILD) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

GILD Beats Q1 Earnings and Sales Estimates, Lowers '26 EPS View

GILD beats Q1 estimates as HIV and Trodelvy sales rise, but shares slip after the company cuts its 2026 EPS outlook.

Gilead (GILD) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Gilead (GILD) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

<ul class="summary-bullets"><li>The company, however, raised its full-year 2026 product sales guidance to $30.0–$30.4 billion, from its previous guidance of $29.6–$30.0 billion.</li><li>Gilead is currently pursuing an aggressive acquisition strategy to bolster its oncology and inflammation pipeline, even as the underlying HIV franchise continues to show resilience.</li><li>Since the start of 2026, the company has announced deals to buy Arcellx, Ouro Medicines, and Tubulis. &nbsp;</li></ul>Shares of Gilead Sciences (GILD) fell 3% in after-hours trading on Thursday despite a solid first-quarter beat and an upward revision to full-year revenue guidance, as investors reacted negatively to a dramatic cut in the company’s 2026 earnings outlook tied to nearly $11.5 billion in acquisition-related charges.Gilead reported first-quarter revenues of $7.0 billion, up 4% from a year earlier, with product sales rising 5% to $6.9 billion. Adjusted and diluted earnings per share came in at $2.03, beating consensus estimates around $1.91 and rising 12% year-over-year. HIV product sales, the company’s largest franchise, grew 10% to $5.0 billion, led by its pills called Biktarvy and Descovy. Cancer drug Trodelvy sales jumped 37% to $402 million, while cell therapy sales slipped 12% amid competitive pressure.The company raised its full-year 2026 product sales guidance to $30.0–$30.4 billion, from its previous guidance of $29.6–$30.0 billion. However, it slashed adjusted loss guidance to a loss of $1.05–$0.65 per share, compared to its previous estimate of earnings per share of $8.45 to $8.85 — a roughly $9.50 per-share reduction — primarily due to anticipated charges and financing costs from its recent acquisitions of Arcellx, Ouro Medicines, and Tubulis.<h2 class="st-heading-2">Gilead’s M&amp;A Spree</h2>Gilead is currently pursuing an aggressive acquisition strategy to bolster its oncology and inflammation pipeline, even as the underlying HIV franchise continues to show resilience.“...we are carefully strengthening our early-stage pipeline to position Gilead well for the long term, typically investing about $1 billion annually in smaller licensing deals, partnerships, and acquisitions,” the company said during its fourth quarter earnings call in February. “We're very ready, we're very proactive and disciplined, but we may not have the urgency of other companies in this sector, so we're gonna be disciplined around that. But I would say that we very much want to continue to add to our pipeline with appropriate, M&amp;A over the course of the coming years as well.”In February, the company agreed to buy longtime partner Arcellx for approximately $7.8 billion, securing full rights to the late-stage CAR-T therapy anito-cel for multiple myeloma. In March, it acquired Ouro Medicines for up to $2.2 billion, adding a pipeline of bispecific T-cell engagers aimed at autoimmune and inflammatory diseases. Most recently, in April, Gilead announced the purchase of German biotech Tubulis for $3.15 billion upfront plus up to $1.85 billion in milestones, gaining next-generation antibody-drug conjugate technology and the clinical-stage asset TUB-040 for ovarian and other solid tumors.<h2 class="st-heading-2">How Did GILD Retail Traders React?</h2>On Stocktwits, retail sentiment around GILD stock stayed within the ‘bearish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.<a href="https://stocktwits.com/symbol/GILD">GILD stock</a> has gained 36% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/iren-stock-soars-after-hours-on-nvidia-2.1-billion-investment-deal/cZXbomSReQo">IREN Stock Soars After Hours On Nvidia’s $2.1B Investment Deal</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Gilead Sciences company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

GILD Stock Slips After Hours On Sharp Earnings Guidance Hit From Massive M&A Spree  

Gilead slashed its full-year earnings outlook primarily due to anticipated charges and financing costs from its recent acquisitions of Arcellx, Ouro Medicines, and Tubulis.

Equity

Gilead slashed its full-year earnings outlook primarily due to anticipated charges and financing costs from its recent acquisitions of Arcellx, Ouro Medicines, and Tubulis.


Gilead Sciences (GILD) Tops Q1 Earnings and Revenue Estimates

Gilead (GILD) delivered earnings and revenue surprises of +7.68% and +0.95%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Gilead Sciences Announces First Quarter Financial Results

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the first quarter 2026. Gilead teams have delivered another strong quarter with 8% year-over-year growth in our base...

Gilead Sciences Likely To Report Higher Q1 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Gilead Sciences (NASDAQ: GILD) will release Q1 earnings on May 7, with analysts expecting $1.91 EPS and $6.92B revenue. Stock closed at $136.30 on April 29.read more...

Mitsubishi UFJ Asset Management Co. Ltd. Acquires 129,186 Shares of Gilead Sciences, Inc. $GILD

Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 5.0% during the fourth quarter, according to the company in its most recent Form...

Equitable Trust Co. Has $6.07 Million Holdings in Gilead Sciences, Inc. $GILD

Equitable Trust Co. increased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 188.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 49,463 shares of the biopharmaceutical company's stock after bu...

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$6.60	--	--	N/A
Q1 '26	$1.91	$2.03	6.31%	BEAT
Q4 '25	$1.81	$1.86	2.76%	BEAT
Q3 '25	$2.13	$2.47	15.85%	BEAT
Q2 '25	$1.96	$2.01	2.55%	BEAT

GILD
Gilead Sciences, Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q1 '26

Historical Earnings

Latest GILD News

GILDGilead Sciences, Inc.